Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

American Journal of Cardiology

Volumn 115, Issue 9, 2015, Pages 1212-1221

  Ballantyne, Christie M ^a,b   Neutel, Joel ^c   Cropp, Anne ^d   Duggan, William ^d   Wang, Ellen Q ^d   Plowchalk, David ^d   Sweeney, Kevin ^d   Kaila, Nitin ^d   Vincent, John ^d   Bays, Harold ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Orange County Research Center   (United States)

^d PFIZER INC   (United States)

^e LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; BOCOCIZUMAB; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN; KEXIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; LIP DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VIRAL UPPER RESPIRATORY TRACT INFECTION; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOLESTEROL, LDL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84927578440     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.02.006     Document Type: Article

References (25)

1. J.D. Horton, J.C. Cohen, and H.H. Hobbs PCSK9: a convertase that coordinates LDL catabolism J Lipid Res 50 suppl 2009 S172 S177
2. M. Abifadel, M. Varret, J.P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, A. Derre, L. Villeger, M. Farnier, I. Beucler, E. Bruckert, J. Chambaz, B. Chanu, J.M. Lecerf, G. Luc, P. Moulin, J. Weissenbach, A. Prat, M. Krempf, C. Junien, N.G. Seidah, and C. Boileau Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156
3. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
4. H. Liang, J. Chaparro-Riggers, P. Strop, T. Geng, J.E. Sutton, D. Tsai, L. Bai, Y. Abdiche, J. Dilley, J. Yu, S. Wu, S.M. Chin, N.A. Lee, A. Rossi, J.C. Lin, A. Rajpal, J. Pons, and D.L. Shelton Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates J Pharmacol Exp Ther 340 2012 228 236
5. R.T. Dadu, and C.M. Ballantyne Lipid lowering with PCSK9 inhibitors Nat Rev Cardiol 11 2014 563 575
6. N. Holford, S.C. Ma, and B.A. Ploeger Clinical trial simulation: a review Clin Pharmacol Ther 88 2010 166 182
7. M.J. Koren, R.P. Giugliano, F.J. Raal, D. Sullivan, M. Bolognese, G. Langslet, F. Civeira, R. Somaratne, P. Nelson, T. Liu, R. Scott, S.M. Wasserman, M.S. Sabatine for the OSLER Investigators Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial Circulation 129 2014 234 243
8. E.M. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
9. E.M. Roth, M.R. Taskinen, H.N. Ginsberg, J.J. Kastelein, H.M. Colhoun, J.G. Robinson, L. Merlet, R. Pordy, and M.T. Baccara-Dinet Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial Int J Cardiol 176 2014 55 61
10. G. Shankar, S. Arkin, L. Cocea, V. Devanarayan, S. Kirshner, A. Kromminga, V. Quarmby, S. Richards, C.K. Schneider, M. Subramanyam, S. Swanson, D. Verthelyi, and S. Yim Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations AAPS J 16 2014 658 673
11. J.C. LaRosa, T.R. Pedersen, R. Somaratne, and S.M. Wasserman Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events Am J Cardiol 111 2013 1221 1229
12. D.J. Blom, T. Hala, M. Bolognese, M.J. Lillestol, P.D. Toth, L. Burgess, R. Ceska, E. Roth, M.J. Koren, C.M. Ballantyne, M.L. Monsalvo, K. Tsirtsonis, J.B. Kim, R. Scott, S.M. Wasserman, E.A. Stein for the DESCARTES Investigators A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
13. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
14. P.M. Ridker LDL cholesterol: controversies and future therapeutic directions Lancet 384 2014 607 617
15. P.M. Rothwell, S.C. Howard, E. Dolan, E. O'Brien, J.E. Dobson, B. Dahlof, P.S. Sever, and N.R. Poulter Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension Lancet 375 2010 895 905
16. S. Bangalore, A. Breazna, D.A. DeMicco, C.C. Wun, and F.H. Messerli Visit-to-visit low density lipoprotein-cholesterol variability and risk of cardiovascular outcomes: insights from the Treating to New Targets trial J Am Coll Cardiol 2015 In press
17. R.P. Giugliano, N.R. Desai, P. Kohli, W.J. Rogers, R. Somaratne, F. Huang, T. Liu, S. Mohanavelu, E.B. Hoffman, S.T. McDonald, T.E. Abrahamsen, S.M. Wasserman, R. Scott, M.S. Sabatine for the LAPLACE-TIMI 57 Investigators Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
18. M.J. Koren, R. Scott, J.B. Kim, B. Knusel, T. Liu, L. Lei, M. Bolognese, and S.M. Wasserman Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
19. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
20. E.A. Stein, D. Gipe, J. Bergeron, D. Gaudet, R. Weiss, R. Dufour, R. Wu, and R. Pordy Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
21. M.J. Koren, P. Lundqvist, M. Bolognese, J.M. Neutel, M.L. Monsalvo, J. Yang, J.B. Kim, R. Scott, S.M. Wasserman, H. Bays for the MENDEL-2 Investigators Anti-PCSK9 monotherapy for hypercholesterolemia - the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2531 2540
22. E. Stroes, D. Colquhoun, D. Sullivan, F. Civeira, R.S. Rosenson, G.F. Watts, E. Bruckert, L. Cho, R. Dent, B. Knusel, A. Xue, R. Scott, S.M. Wasserman, M. Rocco for the GAUSS-2 Investigators Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
23. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
24. H. Scharnagl, M. Nauck, H. Wieland, and W. Marz The Friedewald formula underestimates LDL cholesterol at low concentrations Clin Chem Lab Med 39 2001 426 431
25. S.S. Martin, M.J. Blaha, M.B. Elshazly, P.P. Toth, P.O. Kwiterovich, R.S. Blumenthal, and S.R. Jones Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile JAMA 310 2013 2061 2068